These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

951 related articles for article (PubMed ID: 33724461)

  • 1. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
    Rosiñol L; Beksac M; Zamagni E; Van de Donk NWCJ; Anderson KC; Badros A; Caers J; Cavo M; Dimopoulos MA; Dispenzieri A; Einsele H; Engelhardt M; Fernández de Larrea C; Gahrton G; Gay F; Hájek R; Hungria V; Jurczyszyn A; Kröger N; Kyle RA; Leal da Costa F; Leleu X; Lentzsch S; Mateos MV; Merlini G; Mohty M; Moreau P; Rasche L; Reece D; Sezer O; Sonneveld P; Usmani SZ; Vanderkerken K; Vesole DH; Waage A; Zweegman S; Richardson PG; Bladé J
    Br J Haematol; 2021 Aug; 194(3):496-507. PubMed ID: 33724461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma.
    Togano T; Andoh S; Komuro M; Mitsui Y; Itoi S; Hirai R; Nakamura M; Tanimura A; Sekine R; Takeshita M; Miwa A; Hagiwara S
    Intern Med; 2022 Nov; 61(22):3329-3334. PubMed ID: 35466165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
    Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
    Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed multiple myeloma complicated by cardiac extramedullary plasmacytoma with D-PACE chemotherapy.
    Toocheck C; Pinkhas D
    BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29523615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma].
    Shen LJ; Zhuansun SY; Ni BW; Zhang MY; Lu SS; Hua YN; Xiao D; Huang HH; Han XF; Zhong L; Zhong H; Wang T; Hou J
    Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(36):2861-2867. PubMed ID: 36153871
    [No Abstract]   [Full Text] [Related]  

  • 7. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
    Rosiñol L; Oriol A; Teruel AI; Hernández D; López-Jiménez J; de la Rubia J; Granell M; Besalduch J; Palomera L; González Y; Etxebeste MA; Díaz-Mediavilla J; Hernández MT; de Arriba F; Gutiérrez NC; Martín-Ramos ML; Cibeira MT; Mateos MV; Martínez J; Alegre A; Lahuerta JJ; San Miguel J; Bladé J;
    Blood; 2012 Aug; 120(8):1589-96. PubMed ID: 22791289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
    Rajkumar SV
    Am J Hematol; 2022 Aug; 97(8):1086-1107. PubMed ID: 35560063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
    Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.
    Gagelmann N; Eikema DJ; Koster L; Netelenbos T; McDonald A; Stoppa AM; Fenk R; Anagnostopoulos A; van Gorkom G; Deconinck E; Bulabois CE; Delforge M; Bunjes D; Arcese W; Reményi P; Itälä-Remes M; Thurner L; Bolaman AZ; Nabil Y; Lund J; Labussière-Wallet H; Hayden PJ; Beksac M; Schönland S; Yakoub-Agha I
    Eur J Haematol; 2023 Aug; 111(2):181-190. PubMed ID: 37082839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
    Rajkumar SV
    Am J Hematol; 2013 Mar; 88(3):226-35. PubMed ID: 23440663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.
    Jiménez-Segura R; Granell M; Gironella M; Abella E; García-Guiñón A; Oriol A; Cabezudo E; Clapés V; Soler JA; Escoda L; López-Pardo J; Fernández de Larrea C; Cibeira MT; Tovar N; Isola I; Bladé J; Rosiñol L;
    Eur J Haematol; 2019 May; 102(5):389-394. PubMed ID: 30719772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
    Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
    Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
    Roussel M; Hebraud B; Hulin C; Perrot A; Caillot D; Stoppa AM; Macro M; Escoffre M; Arnulf B; Belhadj K; Karlin L; Garderet L; Facon T; Guo S; Weng J; Dhanasiri S; Leleu X; Moreau P; Attal M
    Leuk Lymphoma; 2020 Jun; 61(6):1323-1333. PubMed ID: 32090636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.
    Bladé J; Fernández de Larrea C; Rosiñol L; Cibeira MT; Jiménez R; Powles R
    J Clin Oncol; 2011 Oct; 29(28):3805-12. PubMed ID: 21900099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis.
    Sekine L; Ziegelmann PK; Manica D; da Fonte Pithan C; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
    Hematol Oncol; 2019 Feb; 37(1):62-74. PubMed ID: 30129104
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 48.